Innorna Clinches Best Startup Nomination at 2026 Prix Galien USA Awards

Innorna, a promising biotechnology company in the clinical stage, has recently announced its nomination for the esteemed 'Best Startup' award at the 2026 Prix Galien USA. Recognized for its innovative approach in developing RNA-based medications, the company has made significant strides with its cutting-edge platform, which employs lipid nanoparticles to deliver messenger RNA (mRNA) formulations.

Innorna's nomination is not just a testament to its innovative technology, but also to its ongoing commitment to expanding the possibilities of RNA therapeutics beyond vaccines. The company's flagship program, IN026, focuses on treating refractory gout through an mRNA-based treatment aimed at effectively lowering uric acid levels. Following FDA approval in March 2026, IN026 marks a pivotal expansion into addressing chronic diseases using mRNA technology.

The Prix Galien is widely regarded as the 'Nobel Prize of the biopharmaceutical industry,' honoring exemplary contributions to medical innovation that enhance human health. The laureates are selected by distinguished committees composed of leading biomedical scientists, private sector executives, and Nobel Prize winners from around the globe.

Linxian Li, the founder and CEO of Innorna, expressed pride in the nomination, stating, "We are honored to be among the finalists for the Prix Galien USA in the category of 'Best Startup.' This recognition acknowledges the hard work and advancements made by our team in developing our clinical project portfolio over several years of dedicated platform engineering. Additionally, it reminds us of our mission to develop RNA-based medicines that offer improved options for patients and enhance their quality of life worldwide."

The winners of the 2026 Prix Galien USA will be revealed during an award ceremony hosted on October 29, 2026, at the American Museum of Natural History in New York.

About Innorna

Innorna is a clinical-stage biotechnology company dedicated to advancing RNA-based medicines through a virtuous cycle of innovation encompassing its platform and clinical project portfolio. This mission is driven by the goal of improving patient quality of life on a global scale. Innorna boasts a growing intellectual property portfolio and has developed a unique and differentiated platform for RNA engineering and administration, which includes a rationally designed library of over 6,000 chemically diverse ionizable lipids, targeted delivery systems for lipid nanoparticles, and mRNA technology.

Their vertically integrated capabilities, ranging from discovery to good manufacturing practice (GMP) compliant production, ensure technical expertise, accelerated development, and strong capital efficiency. The company is focused on building a solid portfolio of mRNA-based clinical projects addressing chronic disease treatments, in vivo immunotherapy, and vaccines. Internally, Innorna has successfully raised $150 million to bolster its innovative research efforts.

With the momentum from this nomination and their ongoing projects, Innorna continues to aspire toward setting new benchmarks in the field of biotechnology, leveraging RNA technology to make a tangible difference in patient care and treatment outcomes.